Friday, September 15, 2023
PathMaker Neurosystems Inc., a company specializing in advanced neuromodulation solutions for neurological disorders, has announced the commencement of a pioneering first-in-human clinical trial to evaluate the MyoRegulator® device for the treatment of amyotrophic lateral sclerosis (ALS). This early feasibility study, conducted at Spaulding Rehabilitation Hospital in Charlestown, MA, aims to assess the safety and feasibility of the MyoRegulator® device in individuals with ALS.
Dr. Nader Yaghoubi, Co-Founder and CEO of PathMaker, expressed excitement about the trial's launch, emphasizing the urgent need for effective treatments for ALS. The company's non-invasive approach targets spinal motor neuron hyperexcitability, a fundamental characteristic of ALS. This clinical evaluation represents a significant milestone for PathMaker in its mission to address the medical needs of ALS patients.
PathMaker is collaborating with Dr. Leon Morales-Quezada, Director of the Integrative Rehabilitation Lab and Research Associate Director of the Spaulding Neuromodulation Center, and Dr. Sabrina Paganoni, Associate Professor of Physical Medicine and Rehabilitation at Spaulding Rehabilitation Hospital, both renowned experts in the field of neuromodulation and ALS. Funding for this ALS trial is provided by the Muscular Dystrophy Association (MDA), the Cullen Education and Research Fund (CERF), and the National Institutes of Health (NIH).
PathMaker's innovative approach relies on their proprietary platform technology, designed to suppress motor neuron hyperexcitability. The MyoRegulator® device, built on this technology, has already demonstrated safety and effectiveness in two completed clinical trials for the treatment of post-stroke spasticity.